The Escherichia coli Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Escherichia coli Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued products.
GlobalData tracks 68 drugs in development for Escherichia coli Infections by 60 companies/universities/institutes. The top development phase for Escherichia coli Infections is discovery with 31 drugs in that stage. The Escherichia coli Infections pipeline has 45 drugs in development by companies and 23 by universities/ institutes. Some of the companies in the Escherichia coli Infections pipeline products market are: Aurobac Therapeutics, Pedanius Therapeutics and University of Strathclyde.
The key targets in the Escherichia coli Infections pipeline products market include Bacterial Cell Membrane, Bacterial Cell Wall, and Burkholderia cenocepacia Acyl Carrier Protein.
The key mechanisms of action in the Escherichia coli Infections pipeline product include Bacterial Cell Membrane Disruptor with five drugs in Phase I. The Escherichia coli Infections pipeline products include seven routes of administration with the top ROA being Intravenous and 18 key molecule types in the Escherichia coli Infections pipeline products market including Small Molecule, and Synthetic Peptide.
Escherichia coli Infections overview
Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. E. coli infections are caused by coming into contact with the feces of humans or animals, or eating or drinking contaminated food or beverage. Symptoms include diarrhea, which may range from mild and watery to severe and bloody; abdominal cramping; pain or tenderness; nausea; and vomiting. The predisposing factors include age, weakened immune system, and eating certain types of food like undercooked hamburger; unpasteurized milk, apple juice, or cider; and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.
For a complete picture of Escherichia coli Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
